Enterprise Value to EBITDA Ratio: Radiopharm Theranostics (RADX)
Radiopharm Theranostics (RADX) is forging scientific alliances with oncologists and nuclear centers to develop precision tools for combating tumors. This chart illustrates an EV/EBITDA of 0.00 as top management scales the clinical asset portfolio. The team relies on rare radiochemists attracted by the uniqueness of nuclear medicine and the startup environment's stock option system.
Comprehensive metric breakdowns and analytics for Radiopharm Theranostics Ltd (RADX)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Debt to Equity Radiopharm Theranostics|RADX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Radiopharm Theranostics|RADX - Company Aggregate Debts|Debts to Book Capitalization Radiopharm Theranostics Limited|RADX - Company Long-Term Indebtedness|Company Short-Term Debts Radiopharm Theranostics|Quick Liquidity radiopharmtheranostics.com
- business earnings and investment ratios data:
RADX - Company Net Income|Expected Profit Radiopharm Theranostics|RADX - Market Cap to Net Income|Forward P/E Multiple Radiopharm Theranostics Limited|RADX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Radiopharm Theranostics Limited|RADX - Operating profit EBITDA|Earnings per share for the last twelve months Radiopharm Theranostics|RADX - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months radiopharmtheranostics.com|RADX - Net earnings per share growth this year|Expected earnings per share growth for next year Radiopharm Theranostics
Fundamental company analysis:Radiopharm Theranostics Limited RADX
The implementation of robotic drug synthesis systems reduces costs, which is reflected in the trend level of Radiopharm Theranostics (RADX) EV/EBITDA. This multiple relates the total enterprise value to operating profit before taxes and amortization, allowing investors to assess the real value of RADX assets while accounting for debt load and determine an entry point during a cyclical decline in value.
Competitor analysis for Radiopharm Theranostics
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Erasca, Inc. (ERAS)|DCTH (delcath.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple YMAB (Y-mAbs Therapeutics, Inc.)|EV/EBITDA Multiple Aura Biosciences Inc AURA|Candel - EV/EBITDA Multiple|ARAY (Accuray, Inc.) - Enterprise Value to Operating Income Before Depreciation|SLS: EV/EBITDA Multiple|ACTU - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Citius Oncology|Company Value to EBITDA TuHURA HURA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protara (TARA)|FATE: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple WHWK (Aadi Bioscience)|Business Value to Operating Income Before Depreciation TCRX|Champions Oncology Corp - EV/EBITDA Multiple|XBIT - EV/EBITDA Multiple|cel-sci.com (CVM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|OS Therapies, Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Artiva Biotherapeutics Inc.|Enterprise Value to EBITDA Ratio Adlai Nortye Limited (ANL)|Enterprise Value to EBITDA Ratio VERU (Veru)|TPST (Tempest Therapeutics Inc) - Business Value to Operating Income Before Depreciation|Xilio Therapeutics - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio RENB (Renovaro Biosciences)|Mural Bio - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation KAPA (Kairos Pharma Ltd)|OKUR: EV/EBITDA Multiple|Company Value to EBITDA CytoMed Therapeutics Limited (GDTC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Curis Inc.|APLM: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple THAR|EV/EBITDA Multiple advanbiomed.com (ADVB)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Genprex GNPX|CLDI: Enterprise Value to Operating Income Before Depreciation|SBFM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Xenetic Biosciences|Salarius Pharmaceuticals (SLRX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PPBT - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio AONC|BGNE (BeiGene Ltd.) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CKPT|Total Company Value to Operating Income Before Depreciation Ratio Elevation Oncology Inc.|EV/EBITDA Multiple ICAD (iCAD)|IKNA - Enterprise Value to EBITDA Ratio|NTBL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Viracta Therapeutics VIRX|MorphoSys Corp (MOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NAYA Biosciences Corp - Business Value to Operating Income Before Depreciation|AAPGV (Ascentage Pharma Group) - EV/EBITDA Multiple
